Neil Dahiya

Boehringer Ingelheim India and RED.Health Join Forces to Enhance Stroke Care Before Hospital Admission in India

Boehringer Ingelheim India, as part of its Angels Initiative, has partnered with RED.Health to formalize efforts aimed at elevating stroke care in pre-hospital scenarios across India. This alliance highlights a mutual dedication to improving emergency healthcare services and facilitating prompt

Boehringer Ingelheim India and RED.Health Join Forces to Enhance Stroke Care Before Hospital Admission in India Read More »

SynaptixBio Points to Growing Gene Silencing Therapy Market, Pioneers ASO for Rare Lethal Condition

Oxford-based SynaptixBio is advancing the development of an antisense oligonucleotide (ASO) aimed at inhibiting the expression of a single mutated gene. The company has identified a significant growth trajectory in the gene silencing market, driven by the advantages it offers

SynaptixBio Points to Growing Gene Silencing Therapy Market, Pioneers ASO for Rare Lethal Condition Read More »

Honoring Leaders in Eye Care with Dr. B T Maskati Memorial Accolades at 2024 Lens Symposium

![Dr. B T Maskati](https://example.com/DrBTMaskati.jpg) In a spectacular event celebrating excellence in vision care, the 2024 Super Specialty Lens Symposium took place in Mumbai, showcasing outstanding contributions in ophthalmology and optometry with the esteemed Dr. B T Maskati Memorial Awards. The

Honoring Leaders in Eye Care with Dr. B T Maskati Memorial Accolades at 2024 Lens Symposium Read More »

Concern Over Increasing Pancreatic Cancer Cases in Southern India: JIPMER Pioneers New Robotic-Assisted Surgery

The Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER), a cornerstone of the government medical structure in southern India, draws a substantial number of patients from nearby states. In response to the growing health issue, specialist teams at JIPMER

Concern Over Increasing Pancreatic Cancer Cases in Southern India: JIPMER Pioneers New Robotic-Assisted Surgery Read More »

Pharmanovia and Lindis Biotech Join Forces to Market Catumaxomab for Treating Malignant Ascites

Pharmanovia, an international pharmaceutical company specializing in novel and revitalized medicines, has augmented its oncology offerings through a licensing agreement for catumaxomab, aimed at treating malignant ascites. With this arrangement, Pharmanovia gains exclusive rights to introduce catumaxomab, a pioneering bi-specific

Pharmanovia and Lindis Biotech Join Forces to Market Catumaxomab for Treating Malignant Ascites Read More »